Evidence map›Paper›PMID 27465476›Full record

Trial reportInternational journal of clinical oncology2017

Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea.

Hiroyoshi Takemoto, Junichi Nishimura, Takamichi Komori, Ho Min Kim, Hirofumi Ota, Rei Suzuki, Masakazu Ikenaga, Masataka Ikeda, Hirofumi Yamamoto, Taroh Satoh and 6 more

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in International journal of clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 3 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. 5HTCancer science · 2021
    Trial
  8. Trial
  9. Global inequitable distribution of seminal studies of chemotherapy-induced nausea and vomiting.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Review
  10. TTD expert consensus on emesis in gastric cancer: evidence-based strategies for prevention and treatment.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Hiroyoshi TakemotoDepartment of Surgery, Kinki Central Hospital, Kurumaduka 3-1, Itami, Hyogo, Japan.
Junichi NishimuraDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Yamadaoka 2-2, Suita, Osaka, Japan. jnishimura@gesurg.med.osaka-u.ac.jp.
Takamichi KomoriDepartment of Surgery, Toyonaka Municipal Hospital, Shibahara 4-14-1, Toyonaka, Osaka, Japan.
Ho Min KimDepartment of Surgery, Rinku General Medical Center, Rinku Ourai Kita 2-23, Izumisano, Osaka, Japan.
Hirofumi OtaDepartment of Digestive Surgery, Ikeda City Hospital, Jyounan 3-1-18, Ikeda, Osaka, Japan.
Rei SuzukiDepartment of Surgery, Itami City Hospital, Koyaike 1-100, Itami, Hyogo, Japan.
Masakazu IkenagaDepartment of Surgery, Higashiosaka City General Hospital, Nishiiwata 3-4-5, Higashiosaka, Osaka, Japan.
Masataka IkedaDepartment of Surgery, National Hospital Organization, Osaka National Hospital, Hoenzaka 2-1-14, Osaka, Osaka, Japan.
Hirofumi YamamotoDivision of Health Sciences, Graduate School of Medicine, Department of Molecular Pathology, Osaka University, Yamadaoka 1-7, Suita, Osaka, Japan.
Taroh SatohDepartment of Frontier-Science for Cancer and Chemotherapy, Graduate School of Medicine, Osaka University, Yamadaoka 2-2, Suita, Osaka, Japan.
Taishi HataDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Yamadaoka 2-2, Suita, Osaka, Japan.
Ichiro TakemasaDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Yamadaoka 2-2, Suita, Osaka, Japan.
Tsunekazu MizushimaDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Yamadaoka 2-2, Suita, Osaka, Japan.
Yuichirou DokiDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Yamadaoka 2-2, Suita, Osaka, Japan.
Masaki MoriDepartment of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Yamadaoka 2-2, Suita, Osaka, Japan.
Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO)
Osaka University · JPHigashi Osaka City General Hospital · JPIkeda Municipal Hospital · JPItami City Hospital · JPKinki Central Hospital · JPOsaka National Hospital · JPToyonaka Municipal Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe previously reported in the SENRI trial on the usefulness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) in colorectal cancer patients receiving an oxaliplatin-based regimen which is classified as moderately emetogenic cancer chemotherapy. In the present subgroup analysis of the SENRI trial, we assessed the risk factors for CINV in colorectal cancer patients who received oxaliplatin-based chemotherapy.

methodsMultivariate logistic regression models were used to assess the impact of aprepitant use and patient characteristics on vomiting and nausea. We also assessed the proportion of CINV in patients by gender.

resultsFemale gender and aprepitant use were associated with the incidence of vomiting and no significant nausea. Significantly more men achieved no vomiting than women (92.9 vs 84.5 % in men and women, respectively; P = 0.0001). The rate of no nausea, complete response, complete protection, and total control was also higher in men. The rate rescue therapy use was significantly higher in women than men. We compared the rate of CINV between aprepitant and control groups and found a significant difference in male patients who achieved no vomiting and complete protection in the overall phase. In women, the rate of no nausea, no vomiting, and total control was higher in the aprepitant group than in the control group.

conclusionsGender and aprepitant use were risk factors for CINV in colorectal patients who received oxaliplatin-based chemotherapy. Aprepitant therapy was more effective for women than for men in the prevention of CINV in colorectal cancer patients receiving an oxaliplatin-based regimen.

Indexed as

AdultAgedAntiemeticsAntineoplastic Combined Chemotherapy ProtocolsAprepitantColorectal NeoplasmsFemaleHumansLogistic ModelsMaleMiddle AgedMorpholinesNauseaOrganoplatinum CompoundsOxaliplatinRisk FactorsAntiemeticsAprepitantfosaprepitantMorpholinesOrganoplatinum CompoundsOxaliplatinAprepitantCINVColorectal cancerGenderOxaliplatinRisk factorsSubgroup analysis

Identifiers

PMID27465476
OpenAlexW2492829203

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.